301 related articles for article (PubMed ID: 34140079)
1. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
Wang L; Bai L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
3. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB; Ha SJ; Kim HR
Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Rotte A; Jin JY; Lemaire V
Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
6. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Kok VC
Front Oncol; 2020; 10():268. PubMed ID: 32185135
[TBL] [Abstract][Full Text] [Related]
7. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
8. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
Lu C; Tan Y
Mol Ther Oncol; 2024 Mar; 32(1):200773. PubMed ID: 38596295
[TBL] [Abstract][Full Text] [Related]
9. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
Yadav R; Hakobyan N; Wang JC
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
[TBL] [Abstract][Full Text] [Related]
10. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
Cancer Biol Med; 2024 May; ():. PubMed ID: 38801082
[TBL] [Abstract][Full Text] [Related]
12. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
[TBL] [Abstract][Full Text] [Related]
13. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
14. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
[TBL] [Abstract][Full Text] [Related]
15. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.
Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.
Li YQ; Chen XM; Si GF; Yuan XM
Biomol Biomed; 2024 Apr; ():. PubMed ID: 38581716
[TBL] [Abstract][Full Text] [Related]
18. [Next generation of anti-immune checkpoints antibodies].
Bonnefoy N; Olive D; Vanhove B
Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
Memon H; Patel BM
Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]